1. Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1987. 'Topical Mitomycin C Therapy for Carcinoma of the Bladder', The Journal of Urology, 138: 1164–66.

    https://doi.org/10.1016/S0022–5347(17)43537–3
  2. Stricker, P.D., and A. B. F. Grant. 1988. 'Relative Value of Antibiotics and Catheter Care in the Prevention of Urinary Tract Infection after Transurethral Prostatic Resection', British Journal of Urology, 61: 494–97.
    https://doi.org/10.1111/j.1464–410X.1988.tb05087.x
  3. Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1990. 'Topical Mitomycin C Therapy for Carcinoma in Situ of the Bladder: A Followup', The Journal of Urology, 143: 34–35.
    https://doi.org/10.1016/S0022–5347(17)39855–5
  4. Stricker, P. D. 1991. 'The Investigation of Male Sexual Dysfunction (Review)', Medical Journal of Australia.
  5. Pryor, K., J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. 'Bacillus Calmette–Guerin (BCG) enhances monocyte– and lymphocyte–mediated bladder tumour cell killing', Br J Cancer, 71: 801–7.
  6. Pryor, K., P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. 'Antiproliferative effects of bacillus Calmette–Guerin and interferon alpha 2b on human bladder cancer cells in vitro', Cancer Immunol Immunother, 41: 309–16.
  7. Stricker, P. 1995. 'Advances in the treatment of superficial bladder cancer: Optimising BCG Immunotherapy Case Discussions', European Urology: Supp, 32–33.
  8. Millard, R. J., P. D. Stricker, and W. Lynch. 1996. 'Risks of self–injection therapy for impotence', The Medical Journal of Australia, 165: 117–18.
  9. Stricker, P. 1996. 'Prostate Cancer: Don't be too casual', The Medical Journal of Australia, 164: 319–20.
  10. Stricker, P., K. Pryor, T. Nicholson, D. Goldstein, D. Golovsky, R. Ferguson, P. Nash, S. Ehsman, J. Rumma, G. Mammen, and R. Penny. 1996. 'Bacillus Calmette–Guerin plus intravesical interferon alpha–2b in patients with superficial bladder cancer', Urology, 48: 957–61; discussion 61–2.
  11. Frydenberg, M., P. D. Stricker, and K. W. Kaye. 1997. 'Prostate cancer diagnosis and management', The Lancet, 349: 1681–87.
    https://doi.org/10.1016/S0140–6736(96)07393–X
  12. Frydenberg, M, G. Duchesne, and P. D. Stricker. 1998. 'Management of localised prostate cancer: state of the art', Med J Aust,169: 11– 2.
  13. Russell, P. J., S. Bennett, and P. Stricker. 1998. 'Growth factor involvement in progression of prostate cancer', Clin Chem, 44: 705–23.
  14. Ricciardelli, C., D. I. Quinn, W. A. Raymond, K. McCaul, P. D. Sutherland, P. D. Stricker, J. J. Grygiel, R. L. Sutherland, V. R. Marshall, W. D. Tilley, and D. J. Horsfall. 1999. 'Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early–stage prostate cancer', Cancer Res, 59: 2324–8.
  15. Kooner, R, and P. Stricker. 2000. 'Lower urinary tract symptoms in the male. Benign prostatic hyperplasia', MedicineToday: 20–33.
  16. Quinn, D. I., S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2000. 'Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy', Cancer Res, 60: 1585–94.
  17. Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. 'Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer', Cancer Res, 61: 423–7.
  18. Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. 'Overexpression of the cell cycle inhibitor p16INK4A in high–grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients', Clin Cancer Res, 7: 544–50.
  19. Horvath, L. G., S. M. Henshall, C. S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, J. A. Gustafsson, and R. L. Sutherland. 2001. 'Frequent loss of estrogen receptor–beta expression in prostate cancer', Cancer Res, 61: 5331–5.
  20. Quinn, D. I., S.M. Henshall, A.M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O’Neill, J. J. Turner, W. Delprado, J. F. Finlayson, R. L. Sutherland, J. J. Grygiel, and P. D. Stricker. 2001. 'Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models', Journal of Clinical Oncology, 19: 3692–705.
    https://doi.org/10.1200/jco.2001.19.16.3692
  21. Stricker, P. 2001. 'Prostate Cancer Part 1. Issues in Screening and Diagnosis', MedicineToday: 20–31.
  22. Stricker, P. 2001. 'Prostate Cancer Part 2. – Options in Treatment', MedicineToday, 2: 30–38.
  23. Graefen, M., P. I. Karakiewicz, I. Cagiannos, E. Klein, P. A. Kupelian, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, P. T. Scardino, and M. W. Kattan. 2002. 'Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer', J Clin Oncol, 20: 951–6.
    https://doi.org/10.1200/jco.2002.20.4.951
  24. Graefen, M., P. I. Karakiewicz, I. Cagiannos, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, E. Klein, P. Kupelian, D. G. Skinner, G. Lieskovsky, B. Bochner, H. Huland, P. G. Hammerer, A. Haese, A. Erbersdobler, J. A. Eastham, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, T. H. van der Kwast, P. T. Scardino, and M. W. Kattan. 2002. 'International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy', J Clin Oncol, 20: 3206–12.
    https://doi.org/10.1200/jco.2002.12.019
  25. Cagiannos, I., P. Karakiewicz, J. A. Eastham, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, P. Kupelian, E. Klein, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2003. 'A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer', J Urol, 170:1798–803.
    https://doi.org/10.1097/01.ju.0000091805.98960.13
  26. Henshall, S. M., D. E. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner–Garden, P. D. Stricker, H. I. Scher, J. J. Grygiel, D. B. Agus, D. H. Mack, and R. L. Sutherland. 2003. 'Survival analysis of genome–wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse', Cancer Res, 63: 4196–203.
  27. Henshall, S. M., D. E. Afar, K. K. Rasiah, L. G. Horvath, K. Gish, I. Caras, V. Ramakrishnan, M. Wong, U. Jeffry, J. G. Kench, D. I. Quinn, J. J. Turner, W. Delprado, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, D. H. Mack, and R. L. Sutherland. 2003. 'Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer', Oncogene, 22: 6005–12.
    https://doi.org/10.1038/sj.onc.1206797
  28. MJ, Stevens, Stricker PD, Saalfeld J, Brenner PC, Kooner R, O'Neill GFA, Duval PJ, Jagavkar RS, Cross P, and Martland J. 2003. 'Treatment of localized prostate cancer using a combination of high dose rate Iridium‐192 brachytherapy and external beam irradiation: Initial Australian experience', Australasian Radiology, 47: 152–60.
    https://doi.org/10.1046/j.0004–8461.2003.01143.x
  29. Quinn, D. I., S. M. Henshall, P. C. Brenner, R. Kooner, D. Golovsky, G. F. O'Neill, J. J. Turner, W. Delprado, J. J. Grygiel, R. L. Sutherland, and P. D. Stricker. 2003. 'Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion', Cancer, 97: 1884–93.
    https://doi.org/10.1002/cncr.11263
  30. Rasiah, K. K., P. D. Stricker, A. M. Haynes, W. Delprado, J. J. Turner, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O'Neill, J. J. Grygiel, R. L. Sutherland, and S. M. Henshall. 2003. 'Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma', Cancer, 98: 2560–5.
    https://doi.org/10.1002/cncr.11850
  31. Adshead, J, and P. Stricker. 2004. 'Localised Prostate Cancer – Questions Patients Ask', MedicineToday, 5: 18–32.
  32. Afar, D. E., V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, C. O'Hara, D. Powers, R. B. DuBridge, I. Caras, R. Winter, T. Anderson, N. Solvason, P. D. Stricker, C. Cordon–Cardo, H. I. Scher, J. J. Grygiel, R. L. Sutherland, R. Murray, V. Ramakrishnan, and D. A. Law. 2004. 'Preclinical validation of anti–TMEFF2–auristatin E– conjugated antibodies in the treatment of prostate cancer', Mol Cancer Ther, 3: 921–32.
  33. Cagiannos, I., P. Karakiewicz, M. Graefen, J. A. Eastham, M. Ohori, F. Rabbani, V. Reuter, T. Wheeler, P. Kupelian, E. Klein, H. Huland, P. G. Hammerer, A. Erbersdobler, F. Schroeder, M. Wildhagen, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2004. 'Is year of radical prostatectomy a predictor of outcome in prostate cancer?', J Urol, 171: 692–6.
    https://doi.org/10.1097/01.ju.0000107260.98031.0e
  34. Haxhimolla, H, S.P. David, K. K. Rasiah, A. M. Haynes, K Luo, D. Golovsky, and P. Stricker. 2004. 'Solitary positive apical margin a treatment dilema', ANZ Journal of Surgery, 74: A1–A8.
  35. Hoch, M, K. K. Rasiah, H Haxhimolla, A. M. Haynes, and P. Stricker. 2004. 'Determining predictors of insignificant cancer in Gleason sum 6 prostate cancer', ANZ Journal of Surgery, 74.
  36. Horvath, L. G., S. M. Henshall, J. G. Kench, D. N. Saunders, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. 'Membranous expression of secreted frizzled–related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro', Clin Cancer Res, 10: 615–25.
  37. Horvath, L. G., S. M. Henshall, J. G. Kench, J. J. Turner, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. 'Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression', Prostate, 59: 234–42.
    https://doi.org/10.1002/pros.10361
  38. Montorsi, F., P. Stricker, E. Jaudinot, C. Wohlhuter, P. Puppo, and P. Teillac. 2004. 'Stratification by outcomes affecting response to Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy', European Urology Supplements, 3: 32.
    https://doi.org/10.1016/S1569–9056(04)90121–2
  39. Rasiah, K. K., S. M. Henshall, J. G. Kench, L. G. Horvath, D. Golovsky, P. C. Brenner, R Kooner, G. O'Neill, J. J. Turner, W. Delprado, C. S. Lee, and P.D. Stricker. 2004. 'Identification of novel markers of prognosis in high grade intraepithelial neoplasia and early prostate cancer', ANZ Journal of Surgery, 74: A1–A8.
  40. Stricker, P., J Matthews, and A. M. Haynes. 2004. 'Radical Prostatectomy: A personal series of 700 cases over 14 years: Evolution in technique', ANZ Journal of Surgery, 74: A1–A8.
  41. Teillac, P., P. Stricker, E. Jaudinot, C. Wohlhuter, and F. Montorsi. 2004. 'Efficacy and safety of Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy', European Urology Supplements, 3: 33.
    https://doi.org/10.1016/S1569–9056(04)90124–8
  42. Bauskin, A. R., D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, H. Johnen, P. J. Russell, W. Barret, P. D. Stricker, J. J. Grygiel, J. G. Kench, S. M. Henshall, R. L. Sutherland, and S. N. Breit. 2005. 'The propeptide mediates formation of stromal stores of PROMIC–1: role in determining prostate cancer outcome', Cancer Res, 65: 2330–6.
    https://doi.org/10.1158/0008–5472.can–04–3827
  43. Finney, G., A. M. Haynes, P. Cross, P. Brenner, A. Boyn, and P. Stricker. 2005. 'Cross–sectional analysis of sexual function after prostate brachytherapy', Urology, 66: 377–81.
    https://doi.org/10.1016/j.urology.2005.03.045
  44. Horvath, L. G., S. M. Henshall, C. S. Lee, J. G. Kench, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2005. 'Lower levels of nuclear beta–catenin predict for a poorer prognosis in localized prostate cancer', Int J Cancer, 113: 415–22.
    https://doi.org/10.1002/ijc.20599
  45. Karakiewicz, P. I., J. A. Eastham, M. Graefen, I. Cagiannos, P. D. Stricker, E. Klein, T. Cangiano, F. H. Schroder, P. T. Scardino, and M. W. Kattan. 2005. 'Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi–institutional assessment of 5831 patients', Urology, 66: 1245–50.
    https://doi.org/10.1016/j.urology.2005.06.108
  46. Macek, P, D Patel, and P. Stricker. 2005. 'Assessing and managing benign prostatic hyperplasia', MedicineToday, 6: 12–22.
  47. Henshall, S. M., L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland. 2006. 'Zinc–alpha2–glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy', J Natl Cancer Inst, 98: 1420–4.
    https://doi.org/10.1093/jnci/djj378
  48. Macek, P, P. Stricker, M. Stevens, R. Jagavkar, V. Chalasani, A.M. Haynes, J Mathews, P. Brenner, D. Golovsky, R Kooner, and F. O'Neill G. 2006. 'Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer', BJU International, 97: 3–3.
    https://doi.org/10.1111/j.1464–410X.2006.06085_12.x
  49. Rasiah, K. K., J. G. Kench, M. Gardiner–Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, F. O'Neill G, J. J. Turner, W. Delprado, C. S. Lee, D. A. Brown, S. N. Breit, J. J. Grygiel, L. G. Horvath, P. D. Stricker, R. L. Sutherland, and S. M. Henshall. 2006. 'Aberrant neuropeptide Y and macrophage inhibitory cytokine–1 expression are early events in prostate cancer development and are associated with poor prognosis', Cancer Epidemiol Biomarkers Prev, 15: 711–6.
    https://doi.org/10.1158/1055–9965.epi–05–0752
  50. Stevens, M., P.D. Stricker, J. Saalfeld, P. Brenner, and R Kooner. 2006. 'Treatment of localised prostate cancer using a combination of high dose‐rate Ir‐192 brachytherapy (HDRB) and external beam radiation therapy (EBRT): a 7 year experience', BJU International, 97: 3–4.
    https://doi.org/10.1111/j.1464–410X.2006.06085_13.x
  51. Chabert, C., Z. Maianski, and P. Stricker. 2007. 'Saw palmetto and lower urinary tract symptoms in men', MedicineToday, 8: 71–72.
  52. Ho, L. L., J. G. Kench, D. J. Handelsman, G. L. Scheffer, P. D. Stricker, J. G. Grygiel, R. L. Sutherland, S. M. Henshall, J. D. Allen, and L. G. Horvath. 2008. 'Androgen regulation of multidrug resistance– associated protein 4 (MRP4/ABCC4) in prostate cancer', Prostate, 68: 1421–9.
    https://doi.org/10.1002/pros.20809
  53. Padma–Nathan, H., A. R. McCullough, L. A. Levine, L. I. Lipshultz, R. Siegel, F. Montorsi, F. Giuliano, and G. Brock. 2008. 'Randomized, double–blind, placebo–controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve–sparing radical prostatectomy', Int J Impot Res, 20: 479–86.
    https://doi.org/10.1038/ijir.2008.33
  54. Sakko, A. J., M. S. Butler, S. Byers, B. J. Reinboth, J. Stahl, J. G. Kench, L. G. Horvath, R. L. Sutherland, P. D. Stricker, S. M. Henshall, V. R. Marshall, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2008. 'Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse', Cancer Epidemiol Biomarkers Prev, 17: 2488–97.
    https://doi.org/10.1158/1055–9965.epi–08–0204
  55. Stricker, P. 2008. 'Approaches to Nerve Sparing Retrograde Athermal Technique', Journal of Robotic Surgery, 2: 105–33.
  56. Stricker, P. 2008. 'Ethical Introduction to Robotic Radical Prostatectomy Surgery for an Experienced Open Surgeon', Journal of Robotic Surgery, 2: 105–33.
  57. Chabert, C., and P. Stricker. 2009. 'Treatment for Localised Prostate Cancer', MedicineToday, 10: 63–66.
  58. Chen, P., R. Thanigasalam, P. Stricker, J Mathews, R. DeBenito, A. M. Haynes, S. M. Henshall, and K. K. Rasiah. 2009. 'The Clinico– Pathological Outcome of Men Undergoing Prostatectomy with PSA < 4 ', BJUI International, 103: 1–48.
    https://doi.org/10.1111/j.1464–410X.2009.09021.x
  59. Chen, P., R. Thanigasalm, S. M. Henshall, A. M. Haynes, J Mathews, and P. Stricker. 2009. 'Prospective Comparative Analysis of Clinico–Pathological Outcomes Between Robotic Assisted and Open Radical Prostatectomy', BJUI International, 103: 1–48.
    https://doi.org/10.1111/j.1464–410X.2009.09021.x
  60. Rasiah, K. K., M. Gardiner–Garden, E. J. Padilla, G. Moller, J. G. Kench, M. C. Alles, S. A. Eggleton, P. D. Stricker, J. Adamski, R. L. Sutherland, S. M. Henshall, and V. M. Hayes. 2009. 'HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer', Mol Cell Endocrinol, 301: 89–96.
    https://doi.org/10.1016/j.mce.2008.11.021
  61. Smith, David P, Madeleine T King, Sam Egger, Martin P Berry, Phillip D Stricker, Paul Cozzi, Jeanette Ward, Dianne L O’Connell, and Bruce K Armstrong. 2009. 'Quality of life three years after diagnosis of localised prostate cancer: population based cohort study', BMJ, 339.
    https://doi.org/10.1136/bmj.b4817
  62. Stricker, P. 2009. 'A Practical Guide on PSA Testing', MedicineToday, 10.
  63. Bianco–Miotto, T., K. Chiam, G. Buchanan, S. Jindal, T. K. Day, M. Thomas, M. A. Pickering, M. A. O'Loughlin, N. K. Ryan, W. A. Raymond, L. G. Horvath, J. G. Kench, P. D. Stricker, V. R. Marshall, R. L. Sutherland, S. M. Henshall, W. L. Gerald, H. I. Scher, G. P. Risbridger, J. A. Clements, L. M. Butler, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2010. 'Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development', Cancer Epidemiol Biomarkers Prev, 19: 2611–22.
    https://doi.org/10.1158/1055–9965.epi–10–0555
  64. Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, R. Pe Benito, and P. Stricker. 2010. 'Robot–assisted laparoscopic prostatectomy: analysis of an experienced open surgeon's learning curve after 300 procedures', J Robot Surg, 3: 229–34.
    https://doi.org/10.1007/s11701–010–0171–5
  65. Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, K. K. Rasiah, R. Pe Benito, W. Delprado, J. Matthews, A. M. Haynes, and P. D. Stricker. 2010. 'Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years', BJU Int, 106: 378–84.
    https://doi.org/10.1111/j.1464–410X.2009.09158.x
  66. Moore, B., R. DeBenito, A. M. Haynes, and P. Stricker. 2010. 'The Impact of Nerve Sparing Surgical Margins Status and Oncological Outcome in Radical Prostatectomy', BJU International Authours Journal Compliation, 105: 1–38.
    https://doi.org/10.1111/j.1464–410X.2010.09122.x
  67. Talantov, D., T. A. Jatkoe, M. Bohm, Y. Zhang, A. M. Ferguson, P. D. Stricker, M. W. Kattan, R. L. Sutherland, J. G. Kench, Y. Wang, and S. M. Henshall. 2010. 'Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy', J Urol, 184: 1521–8.
    https://doi.org/10.1016/j.juro.2010.05.084
  68. Thanigasalam, R., K. K. Rasiah, P. D. Stricker, A. M. Haynes, S. I. Sutherland, R. L. Sutherland, S. M. Henshall, and L. G. Horvath. 2010. 'Stage migration in localized prostate cancer has no effect on the post–radical prostatectomy Kattan nomogram', BJU Int, 105: 642–7.
    https://doi.org/10.1111/j.1464–410X.2009.08842.x
  69. Yip, P. Y., J. G. Kench, K. K. Rasiah, R. P. Benito, C. S. Lee, P. D. Stricker, S. M. Henshall, R. L. Sutherland, and L. G. Horvath. 2011. 'Low AZGP1 expression predicts for recurrence in margin–positive, localized prostate cancer', Prostate, 71: 1638–45.
    https://doi.org/10.1002/pros.21381
  70. Yuen, C., and P. Stricker. 2011. 'Advances in the management of benign prostatic hyperplasia', MedicineToday, 12.
  71. Stricker P.D., Frydenberg M., Kneebone A., and Chopra S..2012. 'Informed prostate cancer risk‐adjusted testing: a new paradigm', BJU International, 110: 30–34.
    https://doi.org/10.1111/j.1464–410X.2012.11621.x
  72. Hossack, T., M. I. Patel, A. Huo, P. Brenner, C. Yuen, D. Spernat, J. Mathews, A. M. Haynes, R. Sutherland, W. del Prado, and P. Stricker. 2012. 'Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy', J Urol, 188: 781–5.
    https://doi.org/10.1016/j.juro.2012.05.006
  73. Huo, A. S., T. Hossack, J. L. Symons, R. PeBenito, W. J. Delprado, P. Brenner, and P. D. Stricker. 2012. 'Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens', J Urol, 187: 2044–9.
    https://doi.org/10.1016/j.juro.2012.01.066
  74. King, M. T., R. Viney, D. P. Smith, I. Hossain, D. Street, E. Savage, S. Fowler, M. P. Berry, M. Stockler, P. Cozzi, P. Stricker, J. Ward, and B. K. Armstrong. 2012. 'Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer', British Journal of Cancer, 106: 638–45.
    https://doi.org/10.1038/bjc.2011.552
  75. Moore, B. M., R. Savdie, R. A. PeBenito, A. M. Haynes, J. Matthews, W. Delprado, K. K. Rasiah, and P. D. Stricker. 2012. 'The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy', BJU Int, 109: 533–8.
    https://doi.org/10.1111/j.1464–410X.2011.10361.x
  76. Savdie, R., L. G. Horvath, R. P. Benito, K. K. Rasiah, A. M. Haynes, M. Chatfield, P. D. Stricker, J. J. Turner, W. Delprado, S. M. Henshall, R. L. Sutherland, and J. G. Kench. 2012. 'High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU Int, 109: 1794–800.
    https://doi.org/10.1111/j.1464–410X.2011.10572.x
  77. Savdie, R., J. Symons, D. Spernat, C. Yuen, R. A. Pe Benito, A. M. Haynes, J. Matthews, K. K. Rasiah, R. S. Jagavkar, C. Yu, G. Fogarty, M. W. Kattan, P. Brenner, R. L. Sutherland, and P. D. Stricker. 2012. 'High–dose rate brachytherapy compared with open radical prostatectomy for the treatment of high–risk prostate cancer: 10 year biochemical freedom from relapse', BJU Int, 110 Suppl 4: 71–6.
    https://doi.org/10.1111/j.1464–410X.2012.11480.x
  78. Smith, D., D O'Connell, A Bang, M. T. King, M. P. Berry, P. Stricker, P. Cozzi, and B. K. Armstrong. 2012. 'Survival in men diagnosed with prostate cancer: 8 to 10 year outcomes from the NSW Prostate Cancer Care and Outcomes Study', Abstract for Sydney Cancer Conference.
  79. Yuen, C., T Hoassack, A. M. Haynes, R. DeBenito, J Mathews, G. Fogarty, R. S. Jagavkar, P. Brenner, and P. Stricker. 2012. 'Impact of percentage of positive biopsy cores on biochemical outcome in patients treated with low–dose rate (Iodine–125) brachytherapy for prostate cancer', The Open Prostate Cancer Journal, 5: 15–19.
  80. Beattie, K., J. Symons, S. Chopra, C. Yuen, R. Savdie, R. Thanigasalam, A. M. Haynes, J. Matthews, P. C. Brenner, K. Rasiah, R. L. Sutherland, and P. D. Stricker. 2013. 'A novel method of bladder neck imbrication to improve early urinary continence following robotic–assisted radical prostatectomy', Journal of Robotic Surgery, 7: 193–99.
    https://doi.org/10.1007/s11701–012–0371–2
  81. Selth, L. A., S. L. Townley, A. G. Bert, P. D. Stricker, P. D. Sutherland, L. G. Horvath, G. J. Goodall, L. M. Butler, and W. D. Tilley. 2013. 'Circulating microRNAs predict biochemical recurrence in prostate cancer patients', Br J Cancer, 109: 641–50.
    https://doi.org/10.1038/bjc.2013.369
  82. Symons, J. L., A. Huo, C. L. Yuen, A. M. Haynes, J. Matthews, R. L. Sutherland, P. Brenner, and P. D. Stricker. 2013. 'Outcomes of transperineal template–guided prostate biopsy in 409 patients', BJU Int, 112: 585–93. https://doi.org/10.1111/j.1464–410X.2012.11657.x
  83. Thanigasalam, R., H. Baumert, P. Stricker, P. Brenner, S. Egger, S. Chopra, J. Symons, R. Savdie, A. Haynes, M. Bohm, A. Elhajj, D. Smith, R. Sutherland, and K. Rasiah. 2013. 'Évaluation de la qualité de vie suite aux traitements actuels du cancer de prostate localisé', Progrès en Urologie, 23: 1100.
    https://doi.org/10.1016/j.purol.2013.08.187
  84. Thompson, J., N. Lawrentschuk, M. Frydenberg, L. Thompson, and P. Stricker. 2013. 'The role of magnetic resonance imaging in the diagnosis and management of prostate cancer', BJU Int, 112 Suppl 2: 6–20.
    https://doi.org/10.1111/bju.12381
  85. Birch, S. E., J. G. Kench, E. Takano, P. Chan, A. L. Chan, K. Chiam, A. S. Veillard, P. Stricker, S. Haupt, Y. Haupt, L. Horvath, and S. B. Fox. 2014. 'Expression of E6AP and PML predicts for prostate cancer progression and cancer–specific death', Ann Oncol, 25: 2392–7.
    https://doi.org/10.1093/annonc/mdu454
  86. Sooriakumaran, P., A. Srivastava, S. F. Shariat, P. D. Stricker, T. Ahlering, C. G. Eden, P. N. Wiklund, R. Sanchez–Salas, A. Mottrie, D. Lee, D. E. Neal, R. Ghavamian, P. Nyirady, A. Nilsson, S. Carlsson, E. Xylinas, W. Loidl, C. Seitz, P. Schramek, C. Roehrborn, X. Cathelineau, D. Skarecky, G. Shaw, A. Warren, W. J. Delprado, A. M. Haynes, E. Steyerberg, M. J. Roobol, and A. K. Tewari. 2014. 'A multinational, multi–institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot– assisted radical prostatectomy patients', Eur Urol, 66: 450–6.
    https://doi.org/10.1016/j.eururo.2013.11.018
  87. Thompson, J. E., S. Egger, M. Bohm, A. M. Haynes, J. Matthews, K. Rasiah, and P. D. Stricker. 2014. 'Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single– surgeon study of 1552 consecutive cases', Eur Urol, 65: 521–31.
    https://doi.org/10.1016/j.eururo.2013.10.030
  88. Thompson, J. E., D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2014. 'Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study', J Urol, 192: 67–74.
    https://doi.org/10.1016/j.juro.2014.01.014
  89. Tran, M, and P. Stricker. 2014. 'An Update on the medical management of benign prostatic hypertrophy', MedicineToday, 15: 72–76.
  90. Valerio, M., P. D. Stricker, H. U. Ahmed, L. Dickinson, L. Ponsky, R. Shnier, C. Allen, and M. Emberton. 2014. 'Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer', Prostate Cancer Prostatic Dis, 17: 343–7.
    https://doi.org/10.1038/pcan.2014.33
  91. Gupta, R., R. O'Connell, A. M. Haynes, P. D. Stricker, W. Barrett, J. J. Turner, W. Delprado, L. G. Horvath, and J. G. Kench. 2015. 'Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?', BJU Int, 116: 343–50.
    https://doi.org/10.1111/bju.12911
  92. Morigi, J. J., P. D. Stricker, P. J. van Leeuwen, R. Tang, B. Ho, Q. Nguyen, G. Hruby, G. Fogarty, R. Jagavkar, A. Kneebone, A. Hickey, S. Fanti, L. Tarlinton, and L. Emmett. 2015. 'Prospective Comparison of 18F–Fluoromethylcholine Versus 68Ga–PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy', J Nucl Med, 56: 1185–90.
    https://doi.org/10.2967/jnumed.115.160382
  93. Rhee, H., J. H. Gunter, P. Heathcote, K. Ho, P. Stricker, N. M. Corcoran, and C. C. Nelson. 2015. 'Adverse effects of androgen–deprivation therapy in prostate cancer and their management', BJU Int, 115 Suppl 5: 3–13.
    https://doi.org/10.1111/bju.12964
  94. Thompson, J. E., A. Hayen, A. Landau, A. M. Haynes, A. Kalapara, J. Ischia, J. Matthews, M. Frydenberg, and P. D. Stricker. 2015. 'Medium–term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer', BJU Int, 115: 884–91.
    https://doi.org/10.1111/bju.12858
  95. Ting, F., M. Tran, M. Böhm, A. Siriwardana, P. J. Van Leeuwen, A. M. Haynes, W. Delprado, R. Shnier, and P. D. Stricker. 2015. 'Focal irreversible electroporation for prostate cancer: functional outcomes and short–term oncological control', Prostate Cancer And Prostatic Diseases, 19: 46.
    https://doi.org/10.1038/pcan.2015.47
  96. Ting, F., P. J. van Leeuwen, W. Delprado, A. M. Haynes, P. Brenner, and P. D. Stricker. 2015. 'Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over–treatment', Prostate, 75: 1768–73.
    https://doi.org/10.1002/pros.23062
  97. Tran, M, and P. Stricker. 2015. 'An update on the medical management of prostate cancer', MedicineToday, 16: 42–48.
  98. Bayliss, D., J. Duff, P. Stricker, and K. Walker. 2016. 'Decision–Making in Prostate Cancer: Active Surveillance Over Other Treatment Options', Urol Nurs, 36: 141–9.
  99. Bruce, HM., P.D. Stricker, R. Gupta, R.R. Savdie, AM. Haynes, KL. Mahon, HM Lin, JG. Kench, and LG. Horvath. 2016. 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin–Positive Localized Prostate Cancer', The Prostate, 76: 1491–500.
    https://doi.org/10.1002/pros.23233
  100. Galvao, D. A., D. R. Taaffe, N. Spry, R. A. Gardiner, R. Taylor, G. P. Risbridger, M. Frydenberg, M. Hill, S. K. Chambers, P. Stricker, T. Shannon, D. Hayne, E. Zopf, and R. U. Newton. 2016. 'Enhancing active surveillance of prostate cancer: the potential of exercise medicine', Nat Rev Urol, 13: 258–65.
    https://doi.org/10.1038/nrurol.2016.46
  101. Kalsbeek, A. M., E. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2016. 'Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer', Aging (Albany NY), 8: 2702–12.
    https://doi.org/10.18632/aging.101044
  102. Penzias, G., A. Janowczyk, A. Singanamalli, M.Rusu, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Böhm, A.M. Haynes, L. Ponsky, S.Viswanath, and A. Madabhushi. 2016. 'AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments', Scientific Reports, 6: 29906.
    https://doi.org/10.1038/srep29906
  103. Thompson, J. E., P. J. van Leeuwen, D. Moses, R. Shnier, P. Brenner, W. Delprado, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2016. 'The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer', J Urol, 195: 1428–35.
    https://doi.org/10.1016/j.juro.2015.10.140
  104. Ting, F., P. J. Van Leeuwen, and P. D. Stricker. 2016. 'Step–by–Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide', J Vasc Interv Radiol, 27: 568.
    https://doi.org/10.1016/j.jvir.2016.01.003
  105. Ting, F., P. J. Van Leeuwen, J. Thompson, R. Shnier, D. Moses, W. Delprado, and P. D. Stricker. 2016. 'Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24–Core Transperineal Template Saturation Mapping Prostate Biopsy', Prostate Cancer, 2016: 3794738.
    https://doi.org/10.1155/2016/3794738
  106. Tran, M., J. Thompson, M. Böhm, M. Pulbrook, D. Moses, R. Shnier, P. Brenner, W. Delprado, AM. Haynes, R. Savdie, and P. Stricker. 2016. 'Combination of multiparametric MRI and transperineal template‐guided mapping biopsy ofthe prostate to identify candidates for hemi‐ablative focal therapy', BJU International, 117: 48–54.
    https://doi.org/10.1111/bju.13090
  107. van Leeuwen, P. J., A. Siriwardana, M. Roobol, F. Ting, D. Nieboer, J. Thompson, W.Delprado, A.M. Haynes, P. Brenner, and P. Stricker. 2016. 'Predicting Low–Risk Prostate Cancer from Transperineal Saturation Biopsies', Prostate Cancer, 2016: 7.
    https://doi.org/10.1155/2016/7105678
  108. van Leeuwen, P. J., P. Stricker, G. Hruby, A. Kneebone, F. Ting, B. Thompson, Q. Nguyen, B. Ho, and L. Emmett. 2016. '(68) Ga–PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment', BJU Int, 117: 732–9.
    https://doi.org/10.1111/bju.13397
  109. Emmett, L., P. J. van Leeuwen, R. Nandurkar, M. J. Scheltema, T. Cusick, G. Hruby, A. Kneebone, T. Eade, G. Fogarty, R. Jagavkar, Q. Nguyen, B. Ho, A. M. Joshua, and P. Stricker. 2017. 'Treatment Outcomes from (68)Ga–PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET', J Nucl Med, 58: 1972–76.
    https://doi.org/10.2967/jnumed.117.196683
  110. Ginsburg, S. B., A. Algohary, S. Pahwa, V. Gulani, L. Ponsky, H. J. Aronen, P. J. Bostrom, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, P. Taimen, R. Villani, P. Stricker, A. R. Rastinehad, I. Jambor, and A. Madabhushi. 2017. 'Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi–institutional study', J Magn Reson Imaging, 46: 184– 93.
    https://doi.org/10.1002/jmri.25562
  111. Grogan, J., R. Gupta, K. L. Mahon, P. D. Stricker, A. M. Haynes, W. Delprado, J. Turner, L. G. Horvath, and J. G. Kench. 2017. 'Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long–term follow–up', BJU Int, 120: 651–58.
    https://doi.org/10.1111/bju.13857
  112. Rusu, M., A. S. Purysko, S.Verma, J. Kiechle, J.Gollamudi, S. Ghose, K.Herrmann, V. Gulani, R. Paspulati, L. Ponsky, M. Böhm, A.M. Haynes, D. Moses, R. Shnier, W. Delprado, J. Thompson, P. Stricker, and A. Madabhushi. 2017. 'Computational imaging reveals shape differences between normal and malignant prostates on MRI', Scientific Reports, 7: 41261.
    https://doi.org/10.1038/srep41261
  113. Scheltema, M. J., J. I. Chang, W. van den Bos, M. Bohm, W. Delprado, I. Gielchinsky, T. M. de Reijke, J. J. de la Rosette, A. R. Siriwardana, R. Shnier, and P. D. Stricker. 2017. 'Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation', Eur Urol Focus.
    https://doi.org/10.1016/j.euf.2017.10.007
  114. Scheltema, M. J., W. van den Bos, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2017. 'Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio–recurrent prostate cancer', BJU Int, 120 Suppl 3: 51–58.
    https://doi.org/10.1111/bju.13991
  115. Siriwardana, A., J. Thompson, and P. Stricker. 2017. 'Personalising prostate cancer care. Part 1: Advances in diagnosis.', MedicineToday, 18: 29–32.
  116. Siriwardana, A., J. Thompson, and P. Stricker. 2017. 'Personalising prostate cancer care. Part 2: Current treatment options', MedicineToday, 18: 28–33.
  117. Siriwardana, A., J. Thompson, P. J. van Leeuwen, S. Doig, A. Kalsbeek, L. Emmett, W. Delprado, D. Wong, H. Samaratunga, A. M. Haynes, G. Coughlin, and P. Stricker. 2017. 'Initial multicentre experience of (68) gallium–PSMA PET/CT guided robot–assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited', BJU Int, 120: 673–81.
    https://doi.org/10.1111/bju.13919
  118. Siriwardana, A., W van den Bos, J. Thompson, R. Shnier, and P.D. Stricker. 2017. 'The role of MRI in prostate cancer: A changing paradigm', MedicineToday, 18.
  119. Symons, J., and P. Stricker. 2017. "Transperineal Prostate Biopsy." In Hinman's Atlas of Urologic Surgery. Elsevier.
  120. Thompson, J., and P. Stricker. 2017. 'MRI improves cost and accuracy of prostate cancer biopsy', Nature Reviews Urology, 15: 6.
    https://doi.org/10.1038/nrurol.2017.185
  121. Thompson, J. E., and P. D. Stricker. 2017. 'Diagnostic accuracy of multi–parametric MRI and transrectal ultrasound–guided biopsy in prostate cancer', Lancet, 389: 767–68.
    https://doi.org/10.1016/s0140–6736(17)30121–6
  122. van den Bos, W., and P. Stricker. 2017. 'Editorial Comment', The Journal of Urology, 197: 653–54.
    https://doi.org/10.1016/j.juro.2016.09.137
  123. van Leeuwen, P. J., L. Emmett, B. Ho, W. Delprado, F. Ting, Q. Nguyen, and P. D. Stricker. 2017. 'Prospective evaluation of 68Gallium– prostate–specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer', BJU Int, 119: 209–15.
    https://doi.org/10.1111/bju.13540
  124. van Leeuwen, P. J., A. Hayen, J. E. Thompson, D. Moses, R. Shnier, M. Bohm, M. Abuodha, A. M. Haynes, F. Ting, J. Barentsz, M. Roobol, J. Vass, K. Rasiah, W. Delprado, and P. D. Stricker. 2017. 'A multiparametric magnetic resonance imaging–based risk model to determine the risk of significant prostate cancer prior to biopsy', BJU Int, 120: 774–81.
    https://doi.org/10.1111/bju.13814
  125. Zhang, A. Y., J. S. Grogan, K. L. Mahon, K. Rasiah, P. Sved, D. R. Eisinger, J. Boulas, A. Vasilaris, S. M. Henshall, P. D. Stricker, J. G. Kench, and L. G. Horvath. 2017. 'A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer', Ann Oncol, 28: 1903–09.
    https://doi.org/10.1093/annonc/mdx247
  126. Algohary, A., S. Viswanath, R. Shiradkar, S. Ghose, S. Pahwa, D. Moses, I. Jambor, R. Shnier, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, A. S. Purysko, S. Verma, L. Ponsky, P. Stricker, and A. Madabhushi. 2018. 'Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings', J Magn Reson Imaging.
    https://doi.org/10.1002/jmri.25983
  127. Emmett, L., R. Nandurkar, P. Van Leeuwen, H. Woo, R. Kooner, D. Ende, G. O’Neill, C. Yuen, B. Ho, Q. Nguyen, A. Hickey, and P. Stricker. 2018. 'Staging with Ga–68 HBED–CC–Glu–NH–CO–NH–Lys (Ahx) PSMA–11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery', European Urology Supplements, 17: e1903.
    https://doi.org/10.1016/S1569–9056(18)32310–8
  128. Kalsbeek, A. M. F., E. K. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2018. 'Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer', Prostate, 78: 25–31.
    https://doi.org/10.1002/pros.23440
  129. Lin, H. M., B. Y. Lee, L. Castillo, C. Spielman, J. Grogan, N. K. Yeung, J. G. Kench, P. D. Stricker, A. M. Haynes, M. M. Centenera, L. M. Butler, S. M. Shreeve, L. G. Horvath, and R. J. Daly. 2018. 'Effect of FAK inhibitor VS–6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78: 308–17.
    https://doi.org/10.1002/pros.23476
  130. Mahon, K. L., P.Stricker, J. Kench, J. Grogan, W. Delprado, J. Turner, L. Horvath, and D. I. Quinn. 2018. 'P53 as a predictor of clinical outcome in localized prostate cancer', Journal of Clinical Oncology, 36: 57–57.
    https://doi.org/10.1200/JCO.2018.36.6_suppl.57
  131. Nair, S.S., PL. Luu, W. Qu, M. Maddugoda, L. Huschtscha, R. Reddel, G. Chenevix–Trench, M. Toso, J. G. Kench, L.G. Horvath, V. M. Hayes, P. Stricker, T.P. Hughes, D.L. White, J.E. J. Rasko, J.J–L Wong, and S.J. Clark. 2018. 'Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten', Epigenetics & Chromatin, 11: 24.
    https://doi.org/10.1186/s13072–018–0194–0
  132. Pidsley, R., M. G. Lawrence, E. Zotenko, B. Niranjan, A. Statham, J. Song, R. M. Chabanon, W. Qu, H. Wang, M. Richards, S. S. Nair, N. J. Armstrong, H. T. Nim, M. Papargiris, P. Balanathan, H. French, T. Peters, S. Norden, A. Ryan, J. Pedersen, J. Kench, R. J. Daly, L. G. Horvath, P. Stricker, M. Frydenberg, R. A. Taylor, C. Stirzaker, G. P. Risbridger, and S. J. Clark. 2018. 'Enduring epigenetic landmarks define the cancer microenvironment', Genome Research, 28: 625–38.
    https://doi.org/10.1101/gr.229070.117
  133. Roach, P. J., R. Francis, L. Emmett, E. Hsiao, A. Kneebone, G. Hruby, T. Eade, Q. A. Nguyen, B. D. Thompson, T. Cusick, M. McCarthy, C. Tang, B. Ho, P. D. Stricker, and A. M. Scott. 2018. 'The Impact of (68)Ga–PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study', J Nucl Med, 59: 82–88.
    https://doi.org/10.2967/jnumed.117.197160
  134. Scheltema, M. J., J. I. Chang, M. Bohm, W. van den Bos, A. Blazevski, I. Gielchinsky, A. M. F. Kalsbeek, P. J. van Leeuwen, T. V. Nguyen, T. M. de Reijke, A. R. Siriwardana, J. E. Thompson, J. J. de la Rosette, and P. D. Stricker. 2018. 'Pair–matched patient–reported quality of life and early oncological control following focal irreversible electroporation versus robot–assisted radical prostatectomy', World J Urol.
    https://doi.org/10.1007/s00345–018–2281–z
  135. Thompson, J. E., S. Egger, M. Bohm, A. R. Siriwardana, A. M. Haynes, J. Matthews, M. J. Scheltema, and P. D. Stricker. 2018. 'Superior Biochemical Recurrence and Long–term Quality–of–life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve–Updated Analysis of a Prospective Single–surgeon Cohort of 2206 Consecutive Cases', Eur Urol, 73: 664–71.
    https://doi.org/10.1016/j.eururo.2017.11.035
  136. van den Bos, W., M. J. Scheltema, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2018. 'Focal irreversible electroporation as primary treatment for localized prostate cancer', BJU Int, 121: 716–24.
    https://doi.org/10.1111/bju.13983
  137. Zhang, A. Y., K. Chiam, Y. Haupt, S. B. Fox, S. Birch, W.Tilley, L. Butler, K. E. Knudsen, C. Cornstock, K. Rasiah, J. Grogan, K.L. Mahon, T. Bianco–Miotto, M. Bohm, S. M. Henshall, W. Delprado, P. Stricker, L. Horvath, and J. Kench. 2018. 'An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy', Journal of Clinical Oncology, 36: 54–54.
    https://doi.org/10.1200/JCO.2018.36.6_suppl.54
  138. Jaratlerdsiri, W., E. K. F. Chan, T. Gong, D. C. Petersen, A. M. F. Kalsbeek, P. A. Venter, P. D. Stricker, M. R. Bornman, and V. M. Hayes. 2018. 'Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment–Naive, High–Risk Prostate Cancer', Cancer Res.
    https://doi.org/10.1158/0008–5472.can–18–0254
  139. Gielchinsky, I., M. J. Scheltema, T. Cusick, J. Chang, R. Shnier, D. Moses, W. Delprado, Q. Nguyen, C. Yuen, A. M. Haynes, and P. D. Stricker. 2018. 'Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50', Res Rep Urol, 10:
    https://doi.org/10.2147/RRU.S169017
  140. Gielchinsky, I., J. Chang, T. Cusick, W. Delprado, Q. Nguyen, C. Yuen, R. Savdie, M. Bohm, A. M. Haynes, M. J. Scheltema, and P. D. Stricker. 2018. 'Prostate cancer in 432 men aged <50 years in the prostate–specific antigen era: a new outlook', BJU Int.
    https://doi.org/10.1111/bju.14586
  141. Scheltema, M. J., J. I. Chang, W. van den Bos, I. Gielchinsky, T. V. Nguyen, T. M. Reijke, A. R. Siriwardana, M. Bohm, J. J. de la Rosette, and P. D. Stricker. 2018. 'Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments', Diagn Interv Radiol, 24: 268–75.
    https://doi.org/10.5152/dir.2018.17374
  142. Penzias, G., A. Singanamalli, R. Elliott, J. Gollamudi, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Bohm, A. M. Haynes, L. Ponsky, P. Fu, P. Tiwari, S. Viswanath, and A. Madabhushi. 2018. 'Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings', PLoS One, 13: e0200730.
    https://doi.org/10.1371/journal.pone.0200730
  143. Thompson, J. E., and P. D. Stricker. 2018. 'MRI improves active surveillance of prostate cancer however biopsy is still crucial', BJU Int, 122: E1–E2.
    https://doi.org/10.1111/bju.14424
  144. Zhang, A. Y., K. Chiam, Y. Haupt, S. Fox, S. Birch, W. Tilley, L. M. Butler, K. Knudsen, C. Comstock, K. Rasiah, J. Grogan, K. L. Mahon, T. Bianco–Miotto, C. Ricciardelli, M. Bohm, S. Henshall, W. Delprado, P. Stricker, L. G. Horvath, and J. G. Kench. 2018. 'An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy', Int J Cancer.
    https://doi.org/10.1002/ijc.31906
  145. van Leeuwen, P. J., M. Donswijk, R. Nandurkar, P. Stricker, B. Ho, S. Heijmink, E. M. K. Wit, C. Tillier, E. van Muilenkom, Q. Nguyen, H. G. van der Poel and L. Emmett (2018). "68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high–risk prostate cancer." BJU Int.
    https://doi.org/10.1111/bju.14506
  146. Nandurkar, R., P. van Leeuwen, P. Stricker, H. Woo, R. Kooner, C. Yuen, G. O'Neill, D. Ende, T. Cusick, B. Ho, A. Hickey and L. Emmett (2019). "(68)Ga–HBEDD PSMA–11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery." Br J Radiol 92(1095): 20180667.
    https://doi.org/10.1259/bjr.20180667
  147. Emmett, L., M. Crumbaker, B. Ho, K. Willowson, P. Eu, L. Ratnayake, R. Epstein, A. Blanksby, L. Horvath, A. Guminski, K. Mahon, C. Gedye, C. Yin, P. Stricker and A. M. Joshua (2019). "Results of a Prospective Phase 2 Pilot Trial of (177)Lu–PSMA–617 Therapy for Metastatic Castration–Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression." Clin Genitourin Cancer 17(1): 15–22.
    https://doi.org/10.1016/j.clgc.2018.09.014
  148. van Leeuwen, P. J., L. Emmett, M. L. Donswijk, P. D. Stricker, F. J. Pos, E. M. K. Wit and H. G. van der Poel (2019). 'Early outcomes after [68Ga]PSMA–PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy | [Vroege oncologische uitkomsten van [68Ga]PSMA–PET/CT–gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie]' Tijdschrift voor Urologie 9(1): 2–8.
    https://doi.org/10.1007/s13629–018–00215–w
  149. Bancroft, E. K., S. Saya, E. C. Page, K. Myhill, S. Thomas, J. Pope, A. Chamberlain, R. Hart, W. Glover, J. Cook, D. J. Rosario, B. T. Helfand, C. Hutten Selkirk, R. Davidson, M. Longmuir, D. M. Eccles, N. Gadea, C. Brewer, J. Barwell, M. Salinas, L. Greenhalgh, M. Tischkowitz, A. Henderson, D. G. Evans, S. S. Buys, R. A. Eeles, IMPACT Collaborators* and N. K. Aaronson (2019). "Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations." BJU Int 123(2): 284–292.
    https://doi.org/10.1111/bju.14412
    *Stricker, P. D. is an author under the IMPACT Collaborators
  150. Scheltema, M. J., J. I. Chang, P. D. Stricker, P. J. van Leeuwen, Q. A. Nguyen, B. Ho, W. Delprado, J. Lee, J. E. Thompson, T. Cusick, A. S. Spriensma, A. R. Siriwardana, C. Yuen, R. Kooner, G. Hruby, G. O'Neill and L. Emmett (2019). "Diagnostic accuracy of (68) Ga– prostate–specific membrane antigen (PSMA) positron–emission tomography (PET) and multiparametric (mp)MRI to detect intermediate–grade intra–prostatic prostate cancer using whole– mount pathology: impact of the addition of (68) Ga–PSMA PET to mpMRI." BJU Int.
    https://doi.org/10.1111/bju.14794
  151. Scheltema, M. J., T. J. O'Brien, W. van den Bos, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, P. D. Stricker, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). "Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole–mount pathology and T2–weighted MRI sequences." Ther Adv Urol 11: 1756287219852305.
    https://doi.org/10.1177/1756287219852305
  152. Feng, Y., W. Jaratlerdsiri, S. M. Patrick, R. J. Lyons, A. M. Haynes, C. C. Collins, P. D. Stricker, M. S. R. Bornman and V. M. Hayes (2019). "Metagenomic analysis reveals a rich bacterial content in high– risk prostate tumors from African men." Prostate 79(15): 1731–1738.
    https://doi.org/10.1002/pros.23897
  153. Quinn, D. I., P. D. Stricker, J. G. Kench, J. Grogan, A. M. Haynes, S. M. Henshall, J. J. Grygiel, W. Delprado, J. J. Turner, L. G. Horvath and K. L. Mahon (2019). "p53 nuclear accumulation as an early indicator of lethal prostate cancer." Br J Cancer 121(7): 578–583.
    https://doi.org/10.1038/s41416–019–0549–8
  154. Emmett, L., R. Tang, R. H. Nandurkar, G. Hruby, P. J. Roach, J. A. Watts, T. Cusick, A. Kneebone, B. Ho, L. Chan, P. van Leeuwen, M. Scheltema, A. Nguyen, C. Yin, A. Scott, C. Tang, M. McCarthy, K. Fullard, M. Roberts, R. Francis and P. Stricker (2019). "3–year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi–center trial." J Nucl Med.
    https://doi.org/10.2967/jnumed.119.235028
  155. Lam, T. B. L., S. MacLennan, P. M. Willemse, M. D. Mason, K. Plass, R. Shepherd, R. Baanders, C. H. Bangma, A. Bjartell, A. Bossi, E. Briers, A. Briganti, K. T. Buddingh, J. W. F. Catto, M. Colecchia, B. W. Cox, M. G. Cumberbatch, J. Davies, N. F. Davis, M. De Santis, P. Dell'Oglio, A. Deschamps, J. F. Donaldson, S. Egawa, C. D. Fankhauser, S. Fanti, N. Fossati, G. Gandaglia, S. Gillessen, N. Grivas, T. Gross, J. P. Grummet, A. M. Henry, A. Ingels, J. Irani, M. Lardas, M. Liew, D. W. Lin, L. Moris, M. I. Omar, K. H. Pang, C. C. Paterson, R. Renard–Penna, M. J. Ribal, M. J. Roobol, M. Roupret, O. Rouviere, G. Sancho Pardo, J. Richenberg, I. G. Schoots, J. P. M. Sedelaar, P. Stricker, D. Tilki, S. Vahr Lauridsen, R. C. N. van den Bergh, T. Van den Broeck, T. H. van der Kwast, H. G. van der Poel, G. van Leenders, M. Varma, P. D. Violette, C. J. D. Wallis, T. Wiegel, K. Wilkinson, F. Zattoni, J. M. O. N'Dow, H. Van Poppel, P. Cornford and N. Mottet (2019). "EAU–EANM–ESTRO–ESUR–SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)." Eur Urol.
    https://doi.org/10.1016/j.eururo.2019.09.020
  156. Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2019). "Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment." BJU Int.
    https://doi.org/10.1111/bju.14951
  157. Amin, A., M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. v. Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson (2020) "The MRI in Active Surveillance (MRIAS); Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.". Journal of Urology 0(0):10.1097/JU.0000000000000693.
    https://doi.org/10.1097/JU.0000000000000693
  158. Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2020). "Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment." BJU Int 125(3): 369–378.
    https://doi.org/10.1111/bju.14951
  159. Luiting, H. B., P. J. van Leeuwen, M. B. Busstra, T. Brabander, H. G. van der Poel, M. L. Donswijk, A. N. Vis, L. Emmett, P. D. Stricker and M. J. Roobol (2020). "Use of gallium–68 prostate–specific membrane antigen positron–emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature." BJU Int 125(2): 206–214.
    https://doi.org/10.1111/bju.14944
  160. Crumbaker, M., E. K. F. Chan, T. Gong, N. Corcoran, W. Jaratlerdsiri, R. J. Lyons, A. M. Haynes, A. A. Kulidjian, A. M. F. Kalsbeek, D. C. Petersen, P. D. Stricker, C. A. M. Jamieson, P. I. Croucher, C. M. Hovens, A. M. Joshua and V. M. Hayes (2020). "The Impact of Whole Genome Data on Therapeutic Decision–Making in Metastatic Prostate Cancer: A Retrospective Analysis." Cancers (Basel) 12(5).
    https://doi.org/10.3390/cancers12051178
    .
  161. Algohary, A., R. Shiradkar, S. Pahwa, A. Purysko, S. Verma, D. Moses, R. Shnier, A. M. Haynes, W. Delprado, J. Thompson, S. Tirumani, A. Mahran, A. R. Rastinehad, L. Ponsky, P. D. Stricker and A. Madabhushi (2020). "Combination of Peri–Tumoral and Intra– Tumoral Radiomic Features on Bi–Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi–Site Study." Cancers (Basel) 12(8).
    https://doi.org.au/10.3390/cancers12082200
    .
  162. Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. “Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).” World Journal of Urology. 2020 Jun 2:1–8.
    http://doi.org.au/10.1007/s00345–020–03275–z

Key aspects

From diagnosis and treatment to rehabilitation and research, I believe my highly experienced team and I bring a multifaceted approach to understanding and helping our patients. A summary of these key aspects of that approach is available here in PDF format. If you are suffering from prostate cancer or have reason to believe you might be, you are welcome to contact us or, intially, complete our comprehensive second opinion form.